Physicians' Academy for Cardiovascular Education

Natural history of DM: Focus on micro- and macrovascular complications

5 Things a cardiologist needs to know about diabetes

10' education - Feb. 13, 2018 - Prof. Kausik Ray, Imperial College London, UK - Online CME

Prof. Ray focuses on micro- and macrovascular disease in type 2 diabetes, their implications, their interrelationship and how these risks can be modified by new glucose-lowering agents.

Video navigation menu

  • Prevalence, risk factors, progression and impact of diabetes 00:38
  • Diabetes is a progressive disease 01:27
  • Macrovascular and microvascular complications and their relationship 03:18
  • New glucose-lowering agents improve CV outcomes 05:50
  • Novel class of diabetes drugs may reduce microvascular complications  09:39

Educational information

This educational video is part of a series called '5 Things a cardiologist needs to know about diabetes' that are aimed to guide cardiologists in management of patients with type 2 diabetes, since the cardiology practice is increasingly confronted with these patients. This series covers five topics that help cardiologists understand what is important when treating patients with diabetes, and what risks these patients face.

This recording was developed under auspices of PACE-cme. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme.

Faculty

Kausik Ray, MD, is a cardiologist, and Professor of Public Health/Honorary Consultant Cardiologist at Imperial College London, United Kingdom.

Disclosures

This educational series is funded by an unrestricted educational grant provided by Merck & Pfizer.

Dowwnload: 5 things a cardiologist should know about diabetes Also view: HbA1c in CVD Also view: Key classes of antidiabeticdrugs

Online-CME

This is available as accredited online CME on coursepath for members. Click the button below to enroll:

Enroll
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: